New York, June 2, 2026, 17:03 (EDT)
Marchex Inc. drifted down in late U.S. trading Tuesday. The shares closed at $1.64, off 1 cent from the last session. The thinly traded AI conversation-intelligence stock had volume of 11,961 shares, market data showed. Investors saw little new out of the company. The pending acquisition stayed in focus.
That’s relevant now since Marchex hasn’t issued any fresh releases to its investor-news feed in the last 24 to 48 hours. The latest updates are still a May 13 first-quarter results release and a May 12 product announcement. So the immediate question stays on execution—if its Archenia deal and new AI products can drive revenue growth without piling on dilution or more integration risk.
Stocks were mostly higher Tuesday. The S&P 500 edged up 0.1%, the Dow rose 0.4%, and the Nasdaq finished with a gain of less than 0.1%. Small-caps outperformed, with the Russell 2000 up 0.9%, according to AP. Marchex moved the other way despite strength in small caps.
Trading took place after the regular Nasdaq session. Nasdaq’s main market is open 9:30 a.m. to 4:00 p.m. Eastern, while after-hours run 4:00 p.m. to 8:00 p.m.
Marchex, with a market cap of roughly $79.7 million, is still a thinly traded micro-cap stock. The low market value means the shares can jump on news, but light trading often leaves the price looking choppy and hard to read.
Marchex’s last full quarter showed a drop in revenue, but losses shrank. The company said first-quarter revenue came in at $10.6 million, down from $11.4 million a year ago. Net loss for the period narrowed to $1.7 million from $2.0 million. Adjusted EBITDA was a loss of $0.1 million, better than the $0.8 million loss reported last year.
Marchex president Troy Hartless said early uptake for Archenia-linked and AI-powered action and outcome tools has been “very encouraging.” Hartless also said there’s potential for AI to help Marchex build products for “new company revenue opportunities.” Business Wire
Marchex’s deal to buy Archenia is built around the May 8 stock purchase agreement. Marchex is set to acquire all of Archenia for $10 million using 6% convertible notes, which can convert into shares at $1.80 each. The sellers could get up to 4 million more Class B shares if the deal hits certain targets for revenue, adjusted EBITDA, integration, or customer retention.
The deal needs sign-off from a majority of disinterested shareholders. Marchex said its special committee of independent directors cleared the plan, citing related parties among some sellers. The company said if all conditions are hit, it expects to finish the transaction in the early part of the third quarter.
Archenia brings the AI story. Marchex calls it a performance-based customer qualification and acquisition firm, saying it uses AI signals and analytics to confirm outcomes—appointments, sales, or high-intent conversations. The approach is pay-per-event: customers pay for verified actions rather than regular software or call data.
Management is touting big numbers. Marchex said the merged business could see about $15 million in quarterly revenue run rate, or $60 million annualized, with growth of 15% to 20% in 2026 and adjusted EBITDA margins at 10% or higher. Those are targets, not current figures.
Marchex (MCHX) Executive Chairman Russell C. Horowitz told analysts on the May 13 earnings call that some bundled offerings might “double revenue on a per customer basis.” He added that the combined business brought a “$100 million revenue opportunity,” according to a Motley Fool transcript. The Motley Fool
Marchex said in its quarterly filing that competition is strong. The company listed call-analytics players like Twilio and Invoca, along with broader tools like Google Ads call tracking. Marchex said rivals could launch similar or better AI features before it does.
The downside isn’t hard to sketch out. If stockholders reject the Archenia deal, or if integration falls behind, or if pilot programs don’t produce steady revenue, Marchex could see slower growth and a stock that keeps trading on low volume. The earn-out shares and convertible notes keep dilution in focus for investors, who will be watching new share creation just as much as revenue growth.
